<b>BioLight Announces First IOPtiMate™ System Sale in Hungary <br /> PR Newswire BioLight Life Sciences Investments Ltd.</b> <br /> <br /> TEL AVIV, Israel, April 13, 2015 /PRNewswire/ -- <br /> <br /> BioLight Life Sciences Investments Ltd. (TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary. <br /> <br /> The IOPtiMate™ system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives. <br /> <br /> "We are pleased that a medical center in Hungary has selected the IOPtiMate™ system as its glaucoma surgery solution and believe that this provides further validation of this unique technology from the ophthalmology community," said Suzana Nahum-Zilberberg, BioLight's chief executive officer. "Recent first sales in Hong Kong and Poland, additional distribution agreements in new territories for the IOPtiMate™ system and its launch in China, further demonstrates our ability to become a truly global player in this marketplace." <br /> <br /> The sale of the first system in Hungary is a result of a marketing campaign to leading physicians and medical centers mainly in Asia and Europe for the IOPtiMate™ system as part of the company's focus on markets with unmet needs for better solutions to treat glaucoma. These marketing efforts have recently resulted in first sales of the IOPtiMate™ system in Hong Kong and Poland, as well as distribution agreements in Peru and Belarus. <br /> <br /> BioLight recently announced a strategic partnership agreement with Rock-One International Holdings Ltd. The agreement will help BioLight maximize its presence in the Chinese market, the second largest healthcare market in the world after the U.S.